Brief: Akeso And Remegen Collaborates On Clinical Study Exploring The Potential Of Pd-1/Ctla-4 Bispecific Antibody With Her-2 Adc Combination Therapy In Gastric Cancer
29/09/2023 14:43
Sept 29 (Reuters) - Akeso Inc 9926.HK :
* AKESO AND REMEGEN COLLABORATES ON CLINICAL STUDY EXPLORING
THE
POTENTIAL OF PD-1/CTLA-4 BISPECIFIC ANTIBODY WITH HER-2 ADC
COMBINATION THERAPY IN GASTRIC CANCER
Source text for Eikon: ID:nPn40NvVZa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals